UK-based SME looking for partners for development of its technology for generation of active biomolecules
A UK-based SME is developing methods of generating bone morphogenetic protein using mammalian cell expression systems to produce significant amounts of active biomolecule. These are being developed with a view to potential therapeutic applications for bone and joint conditions. The SME is looking for research partners with expertise in use of bioactives in bone and joint conditions. The partnership is envisaged as a research cooperation agreement or a technical cooperation agreement.
The UK-based SME is looking to partner with companies, universities and research institutions with an interest in developing actives for the study of / treatment of bones and joint conditions, stem cell research and regenerative medicine. The SME will work with the partner to use the SME's technology to generate bone morphogenic protein in significant quantities and to test it's activity in the partner's test systems. The SME can also supply conditioned media containing BMPs without their purification to enable functional studies of BMP native signalling complex. The SME will expect the partner to feedback on the performance of the generated protein in order to inform the SME's internal development programme. Considering a challenging nature of BMPs, the SME would also welcome collaborations with partners specialising in the purification of growth factors as well as their final formulation, preserving their activity while enabling easy transportation, storage and longer shelf life. It is envisaged that the partnership will take the form of a research cooperation agreement or a technical cooperation agreement.
Biological processes, including tissue regeneration, are governed by proteins. Specific processes are governed by specific proteins that are in the right conformation. It is therefore important for the study of these processes that proteins produced for research have the same shape and therefore activity as those in the natural state. For some proteins that are of particular interest this is a considerable challenge. A UK-based SME has a methodology, developed by generating bone morphogenetic protein (BMP), whereby significant amounts of active protein can be produced. The BMP generated by this new technique has been shown to have biological activity in testing on cells carried out to date. This makes the BMP generated using this technique a potential candidate for developing regenerative therapeutics for bone and joint conditions such as osteoarthritis. The SME is looking to partner with companies, universities and research organisations with an interest and expertise in bioactives in relation to bone and joint conditions to further develop both the BMP as a potential therapeutic and the technique used to make it for other proteins. It is expected that the partner will work with the SME to characterise the performance of the protein in model systems for the study of bone and joint conditions and to improve the technique for generating the protein. The partnership is envisaged as a research cooperation agreement or a technical cooperation agreement depending on the partner and their situation.
Advantages and innovations
Under development/lab tested
Intellectual Property Rights (IPR)